➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Express Scripts
Colorcon
Baxter
Moodys

Last Updated: September 25, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,035,085

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,035,085
Title:Aryl ketone compounds and compositions for delivering active agents
Abstract: The present invention provides aryl ketone compounds and compositions containing them which facilitate the delivery of active agents. The aryl ketone compounds have the formula ##STR00001## or a salt thereof, where n=1 to 9, and R.sup.1 to R.sup.5 are independently hydrogen, C.sub.1 to C.sub.4 alkyl, C.sub.1 to C.sub.4 alkoxy, C.sub.2 to C.sub.4 alkenyl, halogen, hydroxyl, --NH--C(O)--CH.sub.3, or --O--C.sub.6H.sub.5.
Inventor(s): Rath; Parshuram (Yorktown Heights, NY), Gomez-Orellana; Maria Isabel (New Rochelle, NY)
Assignee: EMISPHERE TECHNOLOGIES, INC. (Roseland, NJ)
Application Number:12/045,395
Patent Claims:1. A pharmaceutical composition comprising: (A) at least one biologically active agent selected from human growth hormone, interferon, heparin, low molecular weight heparin, cromolyn sodium, PYY, calcitonin, parathyroid hormone, erythropoietin, and combinations thereof; and (B) a delivery agent of the formula: ##STR00009## or a salt thereof, wherein n is an integer from 1 to 9, R.sup.2 to R.sup.4 are independently hydrogen, C.sub.1 to C.sub.6 alkyl, C.sub.1 to C.sub.6 alkoxy, C.sub.2 to C.sub.6 alkenyl, halogen, hydroxyl, or --O--C.sub.6H.sub.5, and R.sup.1 and R.sup.5 are independently hydrogen, C.sub.1 to C.sub.6 alkoxy, C.sub.2 to C.sub.6 alkenyl, halogen, or --O--C.sub.6H.sub.5, or a salt thereof.

2. A pharmaceutical composition comprising at least one biologically active agent and a compound selected from: 10-(4-Hydroxy-phenyl)-10-oxodecanoic acid; 5-(4-Methoxy-phenyl)-5-oxo-pentanoic acid; 4-(3,5-Difluoro-phenyl)-4-oxo-butyric acid; 5-Oxo-5-phenyl-pentanoic acid; 5-(4-Isopropyl-phenyl)-5-oxo-pentanoic acid; 4-(2-Methoxy-phenyl)-4-oxo-butyric acid; 4-(4-Fluoro-phenyl)-4-oxo-butyric acid; 6-(4-Methoxy-phenyl)-6-oxo-hexanoic acid; 6-(3,4-Dimethyl-phenyl)-6-oxo-hexanoic acid; 4-(3,4-Dimethyl-phenyl)-4-oxo-butyric acid; 6-(2,5-Dichloro-phenyl)-6-oxo-hexanoic acid; 4-(2,5-Dichloro-phenyl)-4-oxo-butyric acid; 8-Oxo-8-phenyl-octanoic acid; 6-(2,5-Difluoro-phenyl)-6-oxo-hexanoic acid; 7-Oxo-7-phenyl-heptanoic acid; 4-(4-Ethyl-phenyl)-4-oxo-butyric acid; 4-(2,4-Difluoro-phenyl)-4-oxo-butyric acid; 4-(4-Butoxy-phenyl)-4-oxo-butyric acid; 4-Oxo-4-(4-propyl-phenyl)-butyric acid; 4-Oxo-4-(4-pentyl-phenyl)-butyric acid; 4-(4-Hexyloxy-phenyl)-4-oxo-butyric acid; 4-(2,5-Difluoro-phenyl)-4-oxo-butyric acid; 6-(3,5-Difluoro-phenyl)-6-oxo-hexanoic acid; 4-Oxo-4-p-tolyl-butyric acid; 6-Oxo-6-phenyl-hexanoic acid; 5-Oxo-5-(4-phenoxy-phenyl)-pentanoic acid; 5-Oxo-5-(3-phenoxy-phenyl)-pentanoic acid; and 7-Oxo-7-(3-phenoxy-phenyl)-heptanoic acid; and salts thereof; wherein said biologically active agent is selected from: Adrenocorticotropin, Amylin, Calcitonin, Sumatriptan Succinate, Calcitonin, Cholecystokinin (CCK), Cromolyn sodium (Sodium Or Disodium Chromoglycate), Desferrioxamine (DFO), Erythropoietin, Exedin, Filgrastim (Granulocyte Colony Stimulating Factor), GM-CSF (sargramostim), Gallium nitrate, Follicle Stimulating Hormone (recombinant and natural), Glucagon, Glucagon-Like Peptide 1 (GLP-1), Glucagon-Like Peptide 2 (GLP-2), Glucocerebrosidase, Gonadotropin releasing hormone, Human Growth Hormone (hGH), Heparin, Unfractionated Heparin, Low Molecular Weight Heparin, Very Low Molecular Weight Heparin, Ultra Low Molecular Weight Heparin, Insulin, Insulin-like growth factor IGF-1, .alpha.-interferon, .beta.-interferon, .gamma.-interferon, Leptin (OB Protein), Leutinizing hormone, leutinizing-hormone-releasing-hormone, follicle stimulating hormone, Oxytocin, Parathyroid hormone (PTH), Peptide YY (PYY), Somatostatin/octreotide, Thrombopoietin, Vasopressin, or any combination thereof.

3. A pharmaceutical composition comprising a compound selected from: 10-(4-Hydroxy-phenyl)-10-oxodecanoic acid; 4-(4-Methoxy-phenyl)-4-oxo-butyric acid; 5-(4-Methoxy-phenyl)-5-oxo-pentanoic acid; 4-(3,5-Difluoro-phenyl)-4-oxo-butyric acid; 5-Oxo-5-phenyl-pentanoic acid; 5-(4-Isopropyl-phenyl)-5-oxo-pentanoic acid; 4-(2-Methoxy-phenyl)-4-oxo-butyric acid; 4-(4-Fluoro-phenyl)-4-oxo-butyric acid; 6-(4-Methoxy-phenyl)-6-oxo-hexanoic acid; 6-(3,4-Dimethyl-phenyl)-6-oxo-hexanoic acid; 4-(3,4-Dimethyl-phenyl)-4-oxo-butyric acid; 6-(2,5-Dichloro-phenyl)-6-oxo-hexanoic acid; 4-(2,5-Dichloro-phenyl)-4-oxo-butyric acid; 8-Oxo-8-phenyl-octanoic acid; 6-(2,5-Difluoro-phenyl)-6-oxo-hexanoic acid; 7-Oxo-7-phenyl-heptanoic acid; 4-(4-Ethyl-phenyl)-4-oxo-butyric acid; 4-(2,4-Difluoro-phenyl)-4-oxo-butyric acid; 4-(4-Butoxy-phenyl)-4-oxo-butyric acid; 4-Oxo-4-(4-propyl-phenyl)-butyric acid; 4-Oxo-4-(4-pentyl-phenyl)-butyric acid; 4-(4-Hexyloxy-phenyl)-4-oxo-butyric acid; 4-(2,5-Difluoro-phenyl)-4-oxo-butyric acid; 5-(4-Chloro-phenyl)-5-oxo-pentanoic acid; 6-(3,5-Difluoro-phenyl)-6-oxo-hexanoic acid; 4-Oxo-4-p-tolyl-butyric acid; 6-Oxo-6-phenyl-hexanoic acid; 5-Oxo-5-(4-phenoxy-phenyl)-pentanoic acid; 5-Oxo-5-(3-phenoxy-phenyl)-pentanoic acid; and 7-Oxo-7-(3-phenoxy-phenyl)-heptanoic acid; and salts thereof; and a biologically active agent selected from human growth hormone, interferon, insulin, heparin, low molecular weight heparin, cromolyn sodium, PYY, calcitonin, parathyroid hormone, erythropoietin, or any combination thereof.

4. The pharmaceutical composition of claim 1, wherein the biologically active agent comprises insulin.

5. The pharmaceutical composition of claim 1, wherein the biologically active agent comprises heparin.

6. The pharmaceutical composition of claim 1, wherein the biologically active agent comprises low molecular weight heparin.

7. The pharmaceutical composition of claim 1, wherein the biologically active agent comprises PYY or a PYY agonist.

8. The pharmaceutical composition of claim 1, wherein the biologically active agent comprises PYY[3-36].

9. The pharmaceutical composition of claim 1, wherein said biologically active agent comprises parathyroid hormone.

10. A dosage unit form comprising (A) a pharmaceutical composition of claim 1; and (B) (a) an excipient (b) a diluent, (c) a disintegrant, (d) a lubricant, (e) a plasticizer, (f) a colorant, (g) a dosing vehicle, or (h) any combination thereof.

11. A method for administering a biologically active agent selected from human growth hormone, interferon, heparin, low molecular weight heparin, cromolyn sodium, PYY, calcitonin, parathyroid hormone, erythropoietin, and combinations thereof to an animal in need of the biologically active agent, the method comprising administering orally to the animal a pharmaceutical composition of claim 1.

12. A method for preparing a pharmaceutical composition, said method comprising mixing: (A) at least one biologically active agent selected from human growth hormone, interferon, heparin, low molecular weight heparin, cromolyn sodium, PYY, calcitonin, parathyroid hormone, erythropoietin, and combinations thereof; and (B) at least one compound of the formula: ##STR00010## or a salt thereof, wherein n is an integer from 1 to 9, R.sup.2 to R.sup.4 are independently hydrogen, C.sub.1 to C.sub.6 alkyl, C.sub.1 to C.sub.6 alkoxy, C.sub.2 to C.sub.6 alkenyl, halogen, hydroxyl, or --O--C.sub.6H.sub.5, and R.sup.1 and R.sup.5 are independently hydrogen, C.sub.1 to C.sub.6 alkoxy, C.sub.2 to C.sub.6 alkenyl, halogen, or --O--C.sub.6H.sub.5, or a salt thereof.

13. The pharmaceutical composition of claim 1, wherein the delivery agent is selected from: 4-Oxo-4-phenyl-butyric acid; 10-(4-Hydroxy-phenyl)-10-oxodecanoic acid; 4-(4-Methoxy-phenyl)-4-oxo-butyric acid; 5-(4-Methoxy-phenyl)-5-oxo-pentanoic acid; 4-(3,5-Difluoro-phenyl)-4-oxo-butyric acid; 5-Oxo-5-phenyl-pentanoic acid; 5-(4-Isopropyl-phenyl)-5-oxo-pentanoic acid; 4-(2-Methoxy-phenyl)-4-oxo-butyric acid; 4-(4-Fluoro-phenyl)-4-oxo-butyric acid; 6-(4-Methoxy-phenyl)-6-oxo-hexanoic acid; 6-(3,4-Dimethyl-phenyl)-6-oxo-hexanoic acid; 4-(3,4-Dimethyl-phenyl)-4-oxo-butyric acid; 6-(2,5-Dichloro-phenyl)-6-oxo-hexanoic acid; 4-(2,5-Dichloro-phenyl)-4-oxo-butyric acid; 8-Oxo-8-phenyl-octanoic acid; 6-(2,5-Difluoro-phenyl)-6-oxo-hexanoic acid; 7-Oxo-7-phenyl-heptanoic acid; 4-(4-Ethyl-phenyl)-4-oxo-butyric acid; 4-(2,4-Difluoro-phenyl)-4-oxo-butyric acid; 4-(4-Butoxy-phenyl)-4-oxo-butyric acid; 4-Oxo-4-(4-propyl-phenyl)-butyric acid; 4-Oxo-4-(4-pentyl-phenyl)-butyric acid; 4-(4-Hexyloxy-phenyl)-4-oxo-butyric acid; 4-(2,5-Difluoro-phenyl)-4-oxo-butyric acid; 5-(4-Chloro-phenyl)-5-oxo-pentanoic acid; 6-(3,5-Difluoro-phenyl)-6-oxo-hexanoic acid; 4-Oxo-4-p-tolyl-butyric acid; 6-Oxo-6-phenyl-hexanoic acid; 5-Oxo-5-(4-phenoxy-phenyl)-pentanoic acid; 5-Oxo-5-(3-phenoxy-phenyl)-pentanoic acid; and 7-Oxo-7-(3-phenoxy-phenyl)-heptanoic acid; and salts thereof.

Details for Patent 9,035,085

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen NEUPOGEN filgrastim VIAL 103353 001 1991-02-20   Start Trial EMISPHERE TECHNOLOGIES, INC. (Roseland, NJ) 2024-05-14 RX search
Amgen NEUPOGEN filgrastim VIAL 103353 002 1991-02-20   Start Trial EMISPHERE TECHNOLOGIES, INC. (Roseland, NJ) 2024-05-14 RX search
Amgen NEUPOGEN filgrastim SYRINGE 103353 003 1991-02-20   Start Trial EMISPHERE TECHNOLOGIES, INC. (Roseland, NJ) 2024-05-14 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
Colorcon
Merck
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.